SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001564590-20-012963
Filing Date
2020-03-26
Accepted
2020-03-26 06:15:39
Documents
12
Period of Report
2020-03-26
Items
Item 8.01: Other Events

Document Format Files

Seq Description Document Type Size
1 8-K ntla-8k_20200326.htm   iXBRL 8-K 52029
  Complete submission text file 0001564590-20-012963.txt   184610

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA ntla-20200326.xsd EX-101.SCH 5768
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE ntla-20200326_lab.xml EX-101.LAB 19475
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE ntla-20200326_pre.xml EX-101.PRE 11626
8 EXTRACTED XBRL INSTANCE DOCUMENT ntla-8k_20200326_htm.xml XML 3550
Mailing Address 40 ERIE STREET SUITE 130 CAMBRIDGE MA 02139
Business Address 40 ERIE STREET SUITE 130 CAMBRIDGE MA 02139 857-285-6200
Intellia Therapeutics, Inc. (Filer) CIK: 0001652130 (see all company filings)

IRS No.: 364785571 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37766 | Film No.: 20743909
SIC: 2835 In Vitro & In Vivo Diagnostic Substances